-+ 0.00%
-+ 0.00%
-+ 0.00%

Bukwang Pharm Q3 2026 YTD Operating Profit Falls 22% Year Over Year to KRW 4.7 Billion

PUBT·10/23/2026 01:00:05
Listen to the news
Bukwang Pharm Q3 2026 YTD Operating Profit Falls 22% Year Over Year to KRW 4.7 Billion
  • Bukwang Pharm’s consolidated operating profit fell 22% year over year to KRW 4.7 billion in the first nine months of 2026.
  • Revenue rose 18% year over year to KRW 162.7 billion, supported by strategic-product prescription growth and increased subsidiary contributions.
  • The operating profit decline stemmed mainly from research and development spending, which climbed 30% year over year to KRW 16.9 billion.
  • Contera Pharma secured US clearance for its CP-012 Phase 2 Parkinson’s trial and is preparing to start the study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bukwang Pharm. Co. Ltd. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.